- Conditions
- Cardiovascular Disease
- Interventions
- Olpasiran, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 406 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 6
- States / cities
- Bridgeport, Connecticut • Jacksonville, Florida • Overland Park, Kansas + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 354
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Coronary Artery Disease
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Chest Pain, Angina, Angina Pectoris, Coronary Artery Disease
- Interventions
- Stress Echocardiography, Coronary CT Angiography
- Procedure
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment
- Interventions
- Optical Coherence Tomography Angiography (OCTA) Imaging, Noninvasive Retinal Amyloid Imaging (NRAI)
- Device
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Acute Kidney Injury
- Interventions
- Remote ischemic preconditioning
- Procedure
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- Not listed
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Coronary Artery Disease
- Interventions
- CT-guided PCI, IVUS-guided PCI
- Device
- Lead sponsor
- CoreAalst BV
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,090 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Minneapolis, Minnesota • Roslyn, New York
- Conditions
- Other Reconstructive Surgery, Plastic Surgery
- Interventions
- Photoacoustic Computed Tomography (PACT) Imaging
- Diagnostic Test
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Wet Macular Degeneration
- Interventions
- Aflibercept Ophthalmic, optovue angiovue
- Drug · Device
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Coronary Disease
- Interventions
- Coronary magnetic resonance angiography imaging
- Procedure
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cardiovascular Disease
- Interventions
- Dalcetrapib, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 936 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 41
- States / cities
- Los Angeles, California • Torrance, California • Boulder, Colorado + 36 more
- Conditions
- Coronary Artery Disease
- Interventions
- Coronary PCI with OCT with Co Registration, Coronary PCI with OCT without Co Registration
- Procedure
- Lead sponsor
- St. Francis Hospital, New York
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Roslyn, New York
- Conditions
- Bone Sarcoma, Soft Tissue Sarcoma
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Non-arteritic Ischemic Optic Neuropathy, Optic Disk Drusen
- Interventions
- Not listed
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- Other
- Eligibility
- 11 Years and older
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Palo Alto, California • San Francisco, California • Boulder, Colorado + 2 more
- Conditions
- Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 50 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Coronary Artery Disease, Angina Pectoris, Chest Pain, Cardiovascular Diseases, Coronary Heart Disease, CHD, CVD, CAD
- Interventions
- Corus CAD (ASGES)
- Diagnostic Test
- Lead sponsor
- CardioDx
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 667 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Dayton, Ohio
- Conditions
- Octa, Stroke, Subarachnoid Hemorrhage, Intracerebral Hemorrhage
- Interventions
- OCTA
- Device
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Prostate Neoplasm
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2030
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota
- Conditions
- Chest Pain, Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease
- Interventions
- CT Coronary Angiography (CTCA), Traditional Strategy
- Diagnostic Test · Procedure
- Lead sponsor
- American College of Radiology
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 1,392 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 5
- States / cities
- Winston-Salem, North Carolina • Hershey, Pennsylvania • Philadelphia, Pennsylvania + 1 more
- Conditions
- Chest Pain, Acute Coronary Syndrome, Pulmonary Embolism, Aortic Dissection
- Interventions
- Not listed
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hemodialysis
- Interventions
- PTA alone without use of the GORE VIABAHN, GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
- Other · Device
- Lead sponsor
- American Access Care
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 3
- States / cities
- Flushing, New York • The Bronx, New York • White Plains, New York
- Conditions
- Age-related Macular Degeneration, Aging
- Interventions
- Normal Macular Health, Early Macular Degeneration, Young Normals
- Other
- Lead sponsor
- Cynthia Owsley
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 556 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Cardiovascular Disease
- Interventions
- Rosuvastatin, Atorvastatin, Cardiac Computed Tomography (CT), Cardiac Magnetic Resonance Image (MRI)
- Drug · Radiation
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Coronary Artery Disease
- Interventions
- PB127 for injectable suspension
- Drug
- Lead sponsor
- Point Biomedical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 428 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • San Francisco, California • Stanford, California + 14 more
- Conditions
- To Assess the Feasibility, Visualization Capability, and Optimal Dosing of ICG Fluorescence Imaging for Intraoperative Assessment of Knee Tissue Perfusion
- Interventions
- Intravenous administration of indocyanine green (SPY Agent Green) 2 mL of SPY Agent Green (5.0 mg dose), Intravenous administration of indocyanine green (SPY Agent Green) 3 mL of SPY Agent Green (7.5 mg dose), Intravenous administration of indocyanine green (SPY Agent Green) 4 mL of SPY Agent Green (10 mg dose), Intravenous administration of indocyanine green (SPY Agent Green)5 mL of SPY Agent Green (12.5 mg dose)
- Combination Product
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 14 Years to 89 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Detroit, Michigan